Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

The Medical News ·
Health & Medicine United Kingdom

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk…

Read original article on The Medical News →

Related news